Subscribe
shutterstock_309001163_bill_perry
Bill Perry / Shutterstock.com
11 May 2020AmericasSarah Morgan

Fed Circuit affirms generic maker’s win over Eagle

The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company  Eagle Pharmaceuticals in a case involving cancer drug Belrapzo (bendamustine hydrochloride injection).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Big Pharma
Fed Circuit limits venue options for generic patent suits
6 November 2020   The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5.
Americas
FDA warns of ‘grave’ knock-on effects from Eagle decision
29 May 2020   The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Big Pharma
Fed Circuit limits venue options for generic patent suits
6 November 2020   The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5.
Americas
FDA warns of ‘grave’ knock-on effects from Eagle decision
29 May 2020   The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.

More on this story

Americas
Teva and Eagle try to block Bendeka generic
1 July 2021   Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.
Big Pharma
Fed Circuit limits venue options for generic patent suits
6 November 2020   The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5.
Americas
FDA warns of ‘grave’ knock-on effects from Eagle decision
29 May 2020   The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.

More features

Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist
Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug
Failure to make findings of fact adds twist to battle over Eliquis in Ireland
Novo Nordisk, Bayer, GSK among giants accused in drug delivery suits